Norgine Successfully Completes Acquisition of Theravia to Expand Rare Disease Portfolio
In a significant move within the pharmaceutical sector, Norgine has successfully completed its acquisition of Theravia, an international company known for specializing in therapies for patients with rare and severe diseases. This acquisition marks a pivotal point in Norgine's strategy to address the unmet medical needs of patients requiring critical treatments.
The announcement was made on August 14, 2025, highlighting the importance of this merger in Norgine’s ongoing commitment to deliver life-changing medications. Following the acquisition, Theravia will operate as a wholly-owned subsidiary of Norgine, allowing for seamless integration of their operations, systems, and teams. This structured process aims to enhance operational efficiencies and improve patient outcomes across Europe and in the Australia/New Zealand region.
Janneke van der Kamp, Norgine's CEO, commented on the acquisition, stating, "We are thrilled to announce the successful completion of this acquisition, as integrating Theravia into our company will deepen our expertise in rare diseases and allow us to expand our offerings in this critical area. This move is instrumental in our growth strategy, focusing on expanding our product range to cater to patients with high unmet medical needs."
Norgine’s commitment to healthcare innovation has been bolstered by this acquisition. With a strong revenue base of over 550 million EUR and more than 120 years of experience in launching transformative products, the company is well-positioned to leverage the potential of Theravia’s therapies. These efforts align with Norgine’s focus on operational excellence and a robust integrated approach, which combines commercial acumen with scientific, regulatory, and clinical expertise.
The integration of Theravia is set to enhance Norgine's ability to serve over 25 million patients annually, delivering high-quality medications efficiently. This merger not only reflects Norgine's agile and innovative ethos but also its dedication to pushing the boundaries of therapeutic innovation in the pharmaceutical industry. The company's strategic objectives include ensuring that the life-changing medications developed by Theravia are accessible to more patients who need them the most.
As Norgine moves forward with this acquisition, industry experts and stakeholders will be watching closely to see how this integration impacts product availability, patient care, and overall market dynamics in the pharmaceutical sector. With a clear mission to address unmet medical needs, Norgine’s acquisition of Theravia stands as a testament to its ongoing commitment to improving health outcomes for patients dealing with rare diseases.
The announcement was made on August 14, 2025, highlighting the importance of this merger in Norgine’s ongoing commitment to deliver life-changing medications. Following the acquisition, Theravia will operate as a wholly-owned subsidiary of Norgine, allowing for seamless integration of their operations, systems, and teams. This structured process aims to enhance operational efficiencies and improve patient outcomes across Europe and in the Australia/New Zealand region.
Janneke van der Kamp, Norgine's CEO, commented on the acquisition, stating, "We are thrilled to announce the successful completion of this acquisition, as integrating Theravia into our company will deepen our expertise in rare diseases and allow us to expand our offerings in this critical area. This move is instrumental in our growth strategy, focusing on expanding our product range to cater to patients with high unmet medical needs."
Norgine’s commitment to healthcare innovation has been bolstered by this acquisition. With a strong revenue base of over 550 million EUR and more than 120 years of experience in launching transformative products, the company is well-positioned to leverage the potential of Theravia’s therapies. These efforts align with Norgine’s focus on operational excellence and a robust integrated approach, which combines commercial acumen with scientific, regulatory, and clinical expertise.
The integration of Theravia is set to enhance Norgine's ability to serve over 25 million patients annually, delivering high-quality medications efficiently. This merger not only reflects Norgine's agile and innovative ethos but also its dedication to pushing the boundaries of therapeutic innovation in the pharmaceutical industry. The company's strategic objectives include ensuring that the life-changing medications developed by Theravia are accessible to more patients who need them the most.
As Norgine moves forward with this acquisition, industry experts and stakeholders will be watching closely to see how this integration impacts product availability, patient care, and overall market dynamics in the pharmaceutical sector. With a clear mission to address unmet medical needs, Norgine’s acquisition of Theravia stands as a testament to its ongoing commitment to improving health outcomes for patients dealing with rare diseases.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.